MedTrace Logo

A Rollover Protocol for Subjects Previously Treated With AGS-003

NCT01482949 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-06-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate clinical response to AGS-003 alone or in combination with sunitinib therapy.

Conditions

Interventions

DRUG

AGS-003

Autologous Dendritic Cell Immunotherapy

Sponsors & Collaborators

  • Argos Therapeutics

    lead INDUSTRY

Principal Investigators

  • Lee F Allen, M.D., Ph.D. · Argos Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01482949 on ClinicalTrials.gov